Rifabutin as salvage therapy for cases of chronic multidrug-resistant pulmonary tuberculosis in Taiwan

Journal of Chemotherapy

Volumn 8, Issue 2, 1996, Pages 137-143

  Lee, C N ^a   Lin, T P ^a   Chang, M F ^b   Jimenez, M V ^b   Dolfi, L ^c,e   Olliaro, P ^c,d  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b Pharmacia   (Taiwan)

^c Pharmacia   (Italy)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e Pharmacia Corporation   (Italy)

Author keywords

Chronic pulmonary tuberculosis; Multidrug resistant Mycobacterium tuberculosis; Rifabutin

Indexed keywords

AMINOSALICYLIC ACID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ADULT; ALOPECIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; COUGHING; DRUG EFFICACY; DRUG RESISTANCE; DRUG TOLERABILITY; FEMALE; HUMAN; JAUNDICE; LEUKOPENIA; LUNG TUBERCULOSIS; MALAISE; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRURITUS; TAIWAN; VOMITING;

EID: 0029995335     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1996.8.2.137     Document Type: Article

References (14)

1. Taiwan Provincial Tuberculosis Control Bureau. The Report of Sixth Prevalence Survey (1982) of Pulmonary Tuberculosis in Taiwan Area, 1985.
2. Liao LC. A Follow-up Study of Patient with Chronic Bacillary Tuberculosis in Taiwan, Public Health Quarterly, 1988.
3. Strong BE, Kubica GP. Isolation and identification of Mycobacterium tuberculosis. A guide for level II Laboratory. Atlanta Georgia, US Department of Health and Human Service, Public Health Service, Centers for Disease Control, Laboratory improvement, Program Office, Laboratory Training and Consultation Division. HHS Publication No. (CDC) 81.8390. 1981.
4. Styblo K. The global aspects of tuberculosis and HIV infection. Bull Int Union Tuberc Lung Dis 1990; 65:28-32.
5. Murray JF. Tuberculosis and human immunodeficiency virus infection during the 1990's. Bull Int Union Tuberc Lung Dis. 1991; 66(1):21-25.
6. Snider DE, Roper WL. The new tuberculosis. N Engl J Med 1992; 326(10):703-705.
7. Chaulet P. Compliance with antituberculosis chemotherapy in developing countries. Tubercle 1987; 68, Suppl: 19-24.
8. Mitchison DA, Ellard GA, Grosset J. New antibacterial drugs for the treatment of mycobacterial disease in man. Br Med Bull 1988; 44(3):757-774.
9. Grosset JH. New approaches in antimycobacterial chemotherapy. Drugs Today 1988; 2-4(5): 291-301.
10. Dhillon J, Mitchison DA. Penetration of rifamycins into mouse peritoneal macrophages. Am Rev Resp Dis 1990; 141(4): A439.
11. Louis TA, Lavori PW, Bailor JC, Polansky M. Crossover and self-controlled design in clinical research. N Engl J Med 1984; 310(1):24-31.
12. Pretet S, Lebeaut A, Parrot R, Truffot C, Grosset J, Dinh-xuan AT, GETIM. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. Eur Respir J 1992; 5:680-684.
13. Lyle MA, O'Brien RJ. Rifabutin (ansamycin LM427) for the treatment of rifampicin resistant tuberculosis. Am Rev Resp Dis 1989; 139(4): A316.
14. Hong Kong Chest Service/British Medical Research Council (1992). A controlled sudy of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tubercle Lung Dis 1992; 73: 59-67.